Crescent BiopharmaCBIO -5.11%10 WACC % is 10.68% as of Jul. 02, 2026, which is 2% above its 10-year median of 10.46. GuruFocus rates CBIO with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,424 Biotechnology companies, Crescent Biopharma ranks worse than 62.43% on this metric.
As of today (2026-07-02), Crescent Biopharma's weighted average cost of capital is 10.68%%. Crescent Biopharma's ROIC % is -1349.79% (calculated using TTM income statement data).
Crescent Biopharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.
*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
For a comprehensive WACC calculation, please access the WACC Calculator.
Crescent Biopharma (NAS:CBIO) WACC % Explanation
Because it costs money to raise capital. A firm that generates higher ROIC % than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.
As of today, Crescent Biopharma's weighted average cost of capital is 10.68%%. Crescent Biopharma's ROIC % is -1349.79% (calculated using TTM income statement data).
Crescent Biopharma earns returns that do not match up to its cost of capital. It will destroy value as it grows.
*Note: The beta of this company cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
Be Aware
1. GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together.
For companies that report quarterly, GuruFocus combines all of the most recent year's quarterly debt data from the beginning of the year to the year-end and calculates the average.
For companies that report semi-annually, GuruFocus combines all of the most recent year's semi-annual debt data from the start of the year to the year-end and calculates the average.
For companies that report annually, GuruFocus combines the beginning and ending annual debt data from the most recent year and then calculates the average.
2. The WACC formula discussed above does not include Preferred Stock. Please adjust if preferred stock is considered.
3. (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
4. GuruFocus uses the latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
Related Terms
Crescent Biopharma WACC % Historical Data
* Premium members only.
The historical data trend for Crescent Biopharma's WACC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Crescent Biopharma's WACC %, along with its competitors' market caps and WACC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Crescent Biopharma WACC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Crescent Biopharma's WACC % distribution charts can be found below:
* The bar in red indicates where Crescent Biopharma's WACC % falls into.
The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. The WACC is commonly referred to as the firm's cost of capital. Generally speaking, a company's assets are financed by debt and equity. WACC is the average of the costs of these sources of financing, each of which is weighted by its respective use in the given situation. By taking a weighted average, we can see how much interest the company has to pay for every dollar it finances.
WACC
=
E
/
(E + D)
*
Cost of Equity
+
D
/
(E + D)
*
Cost of Debt
*
(1 - Tax Rate)
1. Weights:
Generally speaking, a company's assets are financed by debt and equity. We need to calculate the weight of equity and the weight of debt.
The market value of equity (E) is also called "Market Cap". As of today, Crescent Biopharma's market capitalization (E) is $470.978 Mil.
The market value of debt is typically difficult to calculate, therefore, GuruFocus uses book value of debt (D) to do the calculation. It is simplified by adding the latest one-year quarterly average Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation together. As of Mar. 2026, Crescent Biopharma's latest one-year quarterly average Book Value of Debt (D) is $1.643 Mil.
a) weight of equity = E / (E + D) = 470.978 / (470.978 + 1.643) = 0.9965
b) weight of debt = D / (E + D) = 1.643 / (470.978 + 1.643) = 0.0035
2. Cost of Equity:
GuruFocus uses Capital Asset Pricing Model (CAPM) to calculate the required rate of return. The formula is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)
a) GuruFocus uses 10-Year Treasury Constant Maturity Rate as the risk-free rate. It is updated daily. The current risk-free rate is 4.491%. Please go to Economic Indicators page for more information. Please note that we use the 10-Year Treasury Constant Maturity Rate of the country/region where the company is headquartered. If the data for that country/region is not available, then we will use the 10-Year Treasury Constant Maturity Rate of the United States as default.
b) Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. Crescent Biopharma's beta cannot be obtained because it has a price history shorter than 3 years. It will thus be set to 1 as default to calculate WACC.
c) (Expected Return of the Market - Risk-Free Rate of Return) is also called market premium. GuruFocus requires market premium to be 6%.
Cost of Equity = 4.491% + 1 * 6% = 10.491%
3. Cost of Debt:
GuruFocus uses latest TTM Interest Expense divided by the latest one-year quarterly average debt to get the simplified cost of debt.
As of Mar. 2026, Crescent Biopharma's interest expense (positive number) was $1.073 Mil. Its total Book Value of Debt (D) is $1.643 Mil.
Cost of Debt = 1.073 / 1.643 = 65.3074%.
4. Multiply by one minus TTM Tax Rate:
GuruFocus uses the most recent TTM Tax Expense divided by the most recent TTM Pre-Tax Income to calculate the tax rate. The calculated TTM tax rate is limited to between 0% and 100%. If the calculated tax rate is higher than 100%, it is set to 100%. If the calculated tax rate is less than 0%, it is set to 0%.
The latest calculated TTM Tax Rate = 0 / -160.077 = 0%.
Crescent Biopharma's Weighted Average Cost Of Capital (WACC) for Today is calculated as:
WACC
=
E / (E + D)
*
Cost of Equity
+
D / (E + D)
*
Cost of Debt
*
(1 - Tax Rate)
=
0.9965
*
10.491%
+
0.0035
*
65.3074%
*
(1 - 0%)
=
10.68%
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Crescent Biopharma (CBIO) has a WACC % of 10.68% as of Jul. 02, 2026. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Crescent Biopharma and its competitors. This is near median its historical median of 10.46. Over the past decade, Crescent Biopharma's WACC % has ranged from 10.46 to 10.65. According to the industry distribution chart, Crescent Biopharma ranks #889 out of 1424 companies in the Biotechnology industry, placing it in the top 62.4%.
Is Crescent Biopharma's WACC % too high?
Crescent Biopharma's current WACC % of 10.68% is near median its 10-year median of 10.46. Over the past 10 years, this metric has ranged from a low of 10.46 to a high of 10.65. The Biotechnology industry median WACC % is 10.01. Crescent Biopharma's value of 10.68% is 6.7% above this industry median. Based on the distribution chart, Crescent Biopharma ranks #889 out of 1424 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Crescent Biopharma has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Crescent Biopharma's WACC % compare to KYTX and ZURA?
According to the Biotechnology industry distribution chart, Crescent Biopharma ranks #889 out of 1424 companies for WACC %. This places Crescent Biopharma in the lower half of its industry. The industry median WACC % is 10.01. Crescent Biopharma's value of 10.68% is 6.7% above this benchmark. Historically, Crescent Biopharma's own WACC % has ranged from 10.46 to 10.65 over the past decade. While the company's 10-year median is 10.46 vs. the industry median of 10.01, Crescent Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good WACC % for a Biotechnology company?
The median WACC % among Biotechnology companies is 10.01, based on 1,424 companies in the industry. Companies in the top quartile (top 25%) have a WACC % significantly above this median, while those in the bottom quartile fall well below. However, WACC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Crescent Biopharma's current WACC % of 10.68% is 6.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high WACC % mean?
A high WACC % can signal that a stock is expensive relative to its fundamentals. The weighted average cost of capital (WACC) is the average rate a company pays to finance assets. View historical data on Crescent Biopharma and its competitors. For the Biotechnology industry, the median WACC % is 10.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Crescent Biopharma's current WACC % is 10.68%, which is near median its own 10-year median of 10.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Crescent Biopharma stock overvalued right now?
Crescent Biopharma (CBIO) has a current WACC % of 10.68%. The current WACC % is 10.68%, which is near median its 10-year median of 10.46 and 6.7% above the Biotechnology industry median of 10.01. Crescent Biopharma's overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is WACC % calculated?
WACC % is calculated from a company's financial statements. For Crescent Biopharma (CBIO), the current WACC % is 10.68% as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
10GF Score
Get the complete analysis for CBIO
WACC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CBIO has been successfully added to your 